Essential Tips for the Treatment of Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia (BPH) can be...
FDA Approves AstraZeneca’s IMFINZI® (durvalumab) Plus Chemotherapy to Treat Severe Types of Endometrial Cancer
FDA Approves AstraZeneca’s IMFINZI® (durvalumab) Plus Chemotherapy to Treat Severe Types of Endometrial CancerAstraZeneca’s IMFINZI® (durvalumab) plus chemotherapy has been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients struggling with mismatch repair deficient (dMMR) advanced or recurrent endometrial cancer. According to the company’s announcement on Monday, June 18, its latest therapy, IMFINZI® (durvalumab), combined with paclitaxel and carboplatin, followed by the latest IMFINZI monotherapy, have been approved based on prespecified exploratory subgroup results analysis in the DUO-E Phase III.
Please login to comment on this Post